ALKS - Alkermes plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.85
-0.45 (-1.78%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close25.30
Open25.03
Bid24.88 x 1100
Ask26.64 x 1100
Day's Range24.81 - 25.42
52 Week Range24.81 - 51.70
Volume789,739
Avg. Volume1,093,220
Market Cap3.899B
Beta (3Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-1.11
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.67
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of ALKS earnings conference call or presentation 25-Apr-19 12:30pm GMT

    Q1 2019 Alkermes Plc Earnings Call

  • ALXN or ALKS: Which Is the Better Value Stock Right Now?
    Zacks3 days ago

    ALXN or ALKS: Which Is the Better Value Stock Right Now?

    ALXN vs. ALKS: Which Stock Is the Better Value Option?

  • PR Newswire5 days ago

    Alkermes to Present at the UBS Global Healthcare Conference

    DUBLIN , May 14, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global ...

  • PR Newswire6 days ago

    Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences

    -- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings -- DUBLIN , May 13, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today ...

  • Markit12 days ago

    See what the IHS Markit Score report has to say about Alkermes Plc.

    Alkermes Plc NASDAQ/NGS:ALKSView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ALKS with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $4.48 billion over the last one-month into ETFs that hold ALKS are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Alkermes Looks Ahead to Growth
    Motley Fool23 days ago

    Alkermes Looks Ahead to Growth

    Generic competition is dragging down revenue this year, but it has FDA approvals in the wings.

  • Alkermes PLC (ALKS) Q1 2019 Earnings Call Transcript
    Motley Fool23 days ago

    Alkermes PLC (ALKS) Q1 2019 Earnings Call Transcript

    ALKS earnings call for the period ending March 31, 2019.

  • Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1
    Zacks23 days ago

    Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1

    Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.

  • Biogen Looks to 23 Clinical Programs for Growth
    Motley Fool24 days ago

    Biogen Looks to 23 Clinical Programs for Growth

    First-quarter sales were up 11%, but future growth is less certain.

  • Here's Why Shares of Alkermes Sank Today
    Motley Fool24 days ago

    Here's Why Shares of Alkermes Sank Today

    Sales of the drugmaker's schizophrenia drug Aristada disappointed investors.

  • GILD vs. ALKS: Which Stock Is the Better Value Option?
    Zacks24 days ago

    GILD vs. ALKS: Which Stock Is the Better Value Option?

    GILD vs. ALKS: Which Stock Is the Better Value Option?

  • Benzinga24 days ago

    The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...

  • PR Newswire24 days ago

    Alkermes Plc Reports First Quarter 2019 Financial Results

    -- First Quarter Revenues of $223.1 Million , Primarily Driven by ~8% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.62 and Non-GAAP Net Loss ...

  • ACCESSWIRE24 days ago

    Alkermes Plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Alkermes Plc (NASDAQ: ALKS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at 8:30 AM Eastern ...

  • PR Newswire25 days ago

    Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing

    DUBLIN, April 24, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced that C. Todd Nichols, an executive with more than two decades of extensive commercial experience in the biopharmaceutical sector, will become the company's Senior Vice President of Sales and Marketing effective May 13, 2019. He will serve on the Alkermes executive management team and report to Richard Pops, the company's Chief Executive Officer. Mr. Nichols most recently held the position of Vice President, Marketing and Sales, Inflammation and Immunology at Celgene, where he was responsible for developing and managing all aspects of U.S. commercial planning, brand P&L, strategy development, go-to-market modeling and launch execution for ozanimod. "I am excited to join a company with strong leadership, dedicated employees and that is rooted in its mission to make a positive impact on patients struggling with central nervous system (CNS) disorders," said Mr. Nichols.

  • Here’s What Hedge Funds Think About Alkermes Plc (ALKS)
    Insider Monkey25 days ago

    Here’s What Hedge Funds Think About Alkermes Plc (ALKS)

    Does Alkermes Plc (NASDAQ:ALKS) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]

  • Has Alkermes plc (NASDAQ:ALKS) Got Enough Cash?
    Simply Wall St.last month

    Has Alkermes plc (NASDAQ:ALKS) Got Enough Cash?

    Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Alkermes plc (NASDAQ:ALKS), with a market cap of US$5.3b, are often out of the spotlight. While they are less talked about as an i...

  • PR Newswirelast month

    Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results

    DUBLIN , April 18, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 25, 2019 , to discuss the company's ...

  • Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline
    Zackslast month

    Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

    Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzingalast month

    The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 10) Fulgent Genetics Inc (NASDAQ: FLGT ) Intuitive Surgical, ...

  • Alkermes Reports Positive Data From Schizophrenia Study
    Zackslast month

    Alkermes Reports Positive Data From Schizophrenia Study

    Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

  • Reuterslast month

    Alkermes says long-acting drugs could help schizophrenics stay on medication longer

    Alkermes Plc said on Tuesday its long-acting injectable therapy for schizophrenia has helped reduce symptoms and can become an effective option for ensuring patients stay on medication even after being discharged from hospital. The six-month study showed that Alkermes' Aristada, given every two months, was as effective as Johnson & Johnson's monthly injectable Invega Sustenna, with both helping to achieve statistically significant improvements in schizophrenia symptoms. In comparison to long-acting therapies (LATs), commonly prescribed oral antipsychotics are to be taken daily and a brief disruption in treatment can worsen symptoms.

  • PR Newswirelast month

    Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia

    -- Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar ...